



2376 Main Street Billings, Montana U.S.A. Phone: 406-245-5793 Fax: 406-245-6157

FOR IMMEDIATE RELEASE

Billings, Montana, July 1, 2014

MBRCT GRANT AWARDED TO ALL AMERICAN® PHARMACEUTICAL

All American® Pharmaceutical & Natural Foods Corporation (Billings, Montana) has just received a grant in the amount of \$80,000.00 from the Montana Department of Commerce, Montana Board of Research & Commercialization Technology to fund their current study “KarboLyn® A Unique Homopolysaccharide Compound for Glycogen Repletion in Athletes”.

All American® Pharmaceutical has also received grants from the Montana Department of Commerce for Kre-Celazine® and Lyzme5®.

Jeff Golini
CEO & Executive Scientist
All American® Pharmaceutical & Natural Foods Corporation
2376 Main Street, Billings, MT 59105 USA
406-245-5793

www.allamericanpharmaceutical.com
www.getkre-alkalyn.com
www.glutazorb.com
www.kre-celazine.com
www.karbo-lyn.com
www.protalyn.com
www.taxadrol.com

The foregoing may contain “forward-looking statements” for purposes which are based on management’s current information and beliefs as well as on a number of assumptions concerning future events made by management within the meaning of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding All American Pharmaceutical and Natural Foods Corporation’s (“AAP”) positioning and potential plans, products, partners and partner products, and customer acceptance of products. The forward-looking statements in this press release are only predictions and are subject to a number of risks and uncertainties, which could cause actual results to differ materially. AAP assumes no obligation to update the forward-looking statements contained in this press release. Furthermore, no statements made by AAP in this press release, or information contained herein, may be deemed to constitute either an amendment of an existing agreement or an implied new commitment, promise, or legal obligation by AAP to develop or deliver any specific product, feature, or functionality. The development, release, and timing of any product, feature, or functionality described herein remains at AAP’s sole discretion